Developer docs
API playgroundTry for free, no card

Search company profiles

Immune-Onc Therapeutics

Full company profile

uuid0000bws

Namestring
Immune-Onc Therapeutics
Legal namestring
Immune-Onc Therapeutics, Inc.
Websiteurl
immune-onc.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Palo Alto, California, that develops novel therapeutic antibodies for cancer and immunology indications. The company's core technology is a proprietary platform of first-in-class antibodies targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) on myeloid cells, intended to modulate or deplete myeloid cell subsets that drive cancer-associated immune suppression. The lead clinical candidates are IO-108, a fully human IgG4 monoclonal antibody targeting LILRB2 (ILT4) currently in a Phase 1b/2 study in solid tumors including hepatocellular carcinoma, and IO-202, a humanized IgG1 antibody targeting LILRB4 (ILT3) in Phase 1b for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). Earlier-stage programs include IO-106, an anti-LAIR1 antibody for collagen-rich solid tumors, and IO-312, a first-in-class LILRB4 x CD3 bispecific for hematologic malignancies.

Immune-Onc's development model combines internal discovery and clinical execution with strategic collaborations that extend its geographic and combination-therapy reach. Roche sponsors and conducts the global Phase 1b/2 of IO-108 in first-line liver cancer under the Morpheus-Liver program; BeiGene supplies tislelizumab for combination trials in China; and Regeneron supplies Libtayo (cemiplimab) for IO-108 combinations in the U.S. The company retains global development and commercial rights to its core programs and has secured FDA Orphan Drug and Fast Track Designations for IO-202 in AML and CMML, as well as IND clearances in both the U.S. and China.

The company is pre-revenue, generating no product sales; its economics depend on future commercialization of pipeline candidates or partnership/out-licensing transactions. It has raised approximately $131 million in cumulative venture funding, led most recently by a $25 million Series B extension from Triwise Capital with Proxima Ventures, LLS TAP, and Wuxi Biologics. Customers in the commercial sense do not yet exist; revenue-relevant counterparties today are clinical trial sites and patients, with future end-customers expected to be oncologists, specialty pharmacies, and ultimately payers covering oncology and immunology indications.

Short descriptiontext

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class antibody therapeutics that target myeloid cell inhibitory receptors (the LILRB family) to treat blood cancers, solid tumors, and autoimmune diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
myeloid checkpoint inhibitors, cancer immunotherapy antibodies, biopharmaceutical drug development, oncology therapeutics pipeline, LILRB-targeted therapies
Industry1 code
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Immunotherapy / Oncology Biopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical/Biologic Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company. Revenue expected from commercialization of novel myeloid checkpoint inhibitor therapies upon regulatory approval. Pipeline includes IO-108 (Phase 1b/2 solid tumors), IO-202 (Phase 1b blood cancers), IO-106 (preclinical), IO-312 (preclinical).

immune-onc.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of first-in-class therapeutic monoclonal antibodies that target the LILRB family of myeloid cell inhibitory receptors to treat cancer. Its lead clinical-stage candidates are IO-108 (anti-LILRB2 for solid tumors including hepatocellular carcinoma) and IO-202 (anti-LILRB4 for AML, CMML and solid tumors), supplemented by preclinical candidates IO-106 (anti-LAIR1) and IO-312 (LILRB4 x CD3 bispecific).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • IO-202 in CMML: 50% CR rate, 66.7% ORR in 18 evaluable patients vs. 7-17% CR rate for existing therapies
+4 more records
Product overview1 text field

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of novel myeloid checkpoint inhibitors targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB). The pipeline includes IO-108 (anti-LILRB2 for solid tumors), IO-202 (anti-LILRB4 for AML/CMML), IO-106 (anti-LAIR1 for solid tumors), and IO-312 (bispecific anti-LILRB4/CD3 for hematologic malignancies). The company focuses on antibodies that modulate or deplete specific subsets of myeloid cells involved in cancer pathogenesis.

Product and service4 records
1IO-108
CategoryClinical-stage drug candidate (oncology immunotherapy)
Description

IO-108 is a fully human IgG4 monoclonal antibody with high affinity and specificity towards LILRB2 (ILT4). It blocks interaction with multiple ligands (HLA-G, ANGPTLs, SEMA4A, CD1d) involved in cancer-associated immune suppression, functioning as a myeloid checkpoint inhibitor to promote innate and adaptive anti-cancer immunity. It is currently in Phase 1b/2 clinical development for solid tumors including hepatocellular carcinoma.

2IO-202
CategoryClinical-stage drug candidate (oncology immunotherapy)
Description

IO-202 is a first-in-class humanized IgG1 antagonist antibody that binds LILRB4 (ILT3) with high affinity and depletes LILRB4-positive cells via antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). It converts 'don't kill me' to 'kill me' signals by activating T cell killing, and inhibits infiltration of blood cancer cells. It is in Phase 1b development for acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors.

3IO-106
CategoryPreclinical drug candidate (oncology immunotherapy)
Description

IO-106 is a first-in-class antagonist monoclonal antibody targeting LAIR1 (Leukocyte-Associated Immunoglobulin-Like Receptor 1). It reverses collagen-mediated immune suppression on T cells and myeloid cells in the solid tumor microenvironment, with broad potential in collagen-rich solid tumors.

4IO-312
CategoryPreclinical bispecific antibody (oncology immunotherapy)
Description

IO-312 is a first-in-class LILRB4-directed bispecific monoclonal antibody with high affinity binding to LILRB4 and low affinity binding to CD3. The differential affinity design maximizes anti-tumor effect while minimizing cytokine release-related toxicities. It has cross-reactivity to non-human primate LILRB4 and CD3 to enable preclinical toxicology assessment, with potential application in AML and other hematologic malignancies.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-02-20
Description

Clinical trial collaboration for IO-108 in global Phase 1b/2 study. Roche sponsors and conducts the trial evaluating IO-108 with atezolizumab and bevacizumab for first-line hepatocellular carcinoma treatment as part of Roche's Morpheus-Liver program. Roche provides clinical supply and manages study operations.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-10-17
Description

Clinical supply agreement for IO-108 in combination with Regeneron's anti-PD-1 therapy Libtayo (cemiplimab). Regeneron provides cemiplimab for ongoing clinical development program; Immune-Onc retains global rights to IO-108.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-10-10
Description

Clinical trial collaboration and supply agreement to evaluate IO-108 and IO-202 in combination with BeiGene's anti-PD-1 antibody tislelizumab in China. Immune-Onc sponsors and funds clinical trials; BeiGene provides tislelizumab.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic research collaboration with academic institution; scientific founder Dr. Chengcheng (Alec) Zhang is faculty member. Pioneering research on LILRB family published in Nature.

5Albert Einstein College of Medicine
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic research collaboration for myeloid checkpoint target research and validation.

immune-onc.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic research collaboration for oncology research programs.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Pionyr Immunotherapeutics
TypeDirect peer
Description

Pionyr is a clinical-stage biotech developing antibody therapeutics that target myeloid cell receptors in the tumor microenvironment (TREM2, TREM1). It competes with Immune-Onc on the same thesis of depleting or reprogramming suppressive myeloid cells to enable anti-tumor immunity.

TypeDirect peer
Description

Compugen uses computational biology to identify novel immune checkpoints, including myeloid targets such as PVRIG and TIGIT-axis pathways. Both companies pursue novel checkpoint biology discovered through proprietary target-identification platforms and translate them into antibody therapeutics.

TypeDirect peer
Description

Trillium developed SIRPα/CD47 myeloid checkpoint inhibitors for hematologic malignancies before being acquired by Pfizer. It is the most advanced direct precedent for a small-cap biotech successfully translating myeloid checkpoint biology into pivotal-stage assets, directly comparable to Immune-Onc's LILRB strategy.

4Surface Oncology
TypeDirect peer
Description

Surface Oncology developed immuno-oncology antibodies targeting myeloid and stromal cells in the tumor microenvironment, including ILT-related programs. Its pipeline and scientific rationale closely overlap with Immune-Onc's LILRB-directed approach.

5Innate Pharma
TypeDirect peer
Description

Innate Pharma develops antibody-based immunotherapies targeting myeloid and NK cell pathways for cancer. Its focus on innate immune modulation (e.g., NKG2A) places it in direct strategic overlap with Immune-Onc's myeloid checkpoint thesis.

TypeRegional player
Description

Nkarta is a clinical-stage cell therapy company developing allogeneic NK cell therapies for hematologic malignancies including AML. While the modality (cell therapy vs. antibody) and target cell type differ, it overlaps with Immune-Onc in clinical indication (AML/CMML) and in the strategy of redirecting innate immunity against blood cancers.

TypeEmerging player
Description

Mereo is a clinical-stage biopharma developing therapies for rare hematologic conditions and cancers, including AML. It overlaps with Immune-Onc on indication strategy in myeloid blood cancers and on the orphan-drug, accelerated-approval playbook.

TypeEmerging player
Description

Werewolf is developing tumor-microenvironment-activated immunotherapies (PREDATOR platform) that deliver immune agonists selectively into the tumor. It is comparable as another small-cap IO biotech targeting the same tumor-microenvironment biology that Immune-Onc addresses via myeloid checkpoints.

TypeDirect peer
Description

Arcus is a clinical-stage immuno-oncology company with programs targeting adenosine (CD73/A2AR) and other myeloid-suppressive pathways. It competes for the same combination-therapy slot in tumors like HCC where Immune-Onc's IO-108 is being evaluated alongside checkpoint inhibitors.

TypeEmerging player
Description

Bolt develops immune-stimulating antibody-drug conjugates (ISACs) designed to activate myeloid cells in the tumor microenvironment. While the modality differs from naked mAbs, both companies target the same biological insight: engaging myeloid cells to convert cold tumors to hot.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks3 records

Each record includes

Headline, Details, Source

Key highlights14 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Immune-Onc Therapeutics

Cancer Immunotherapy / Oncology Biopharmaceuticalsimmune-onc.com

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class antibody therapeutics that target myeloid cell inhibitory receptors (the LILRB family) to treat blood cancers, solid tumors, and autoimmune diseases.

What Immune-Onc Therapeutics does

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Palo Alto, California, that develops novel therapeutic antibodies for cancer and immunology indications. The company's core technology is a proprietary platform of first-in-class antibodies targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) on myeloid cells, intended to modulate or deplete myeloid cell subsets that drive cancer-associated immune suppression. The lead clinical candidates are IO-108, a fully human IgG4 monoclonal antibody targeting LILRB2 (ILT4) currently in a Phase 1b/2 study in solid tumors including hepatocellular carcinoma, and IO-202, a humanized IgG1 antibody targeting LILRB4 (ILT3) in Phase 1b for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). Earlier-stage programs include IO-106, an anti-LAIR1 antibody for collagen-rich solid tumors, and IO-312, a first-in-class LILRB4 x CD3 bispecific for hematologic malignancies.

Immune-Onc's development model combines internal discovery and clinical execution with strategic collaborations that extend its geographic and combination-therapy reach. Roche sponsors and conducts the global Phase 1b/2 of IO-108 in first-line liver cancer under the Morpheus-Liver program; BeiGene supplies tislelizumab for combination trials in China; and Regeneron supplies Libtayo (cemiplimab) for IO-108 combinations in the U.S. The company retains global development and commercial rights to its core programs and has secured FDA Orphan Drug and Fast Track Designations for IO-202 in AML and CMML, as well as IND clearances in both the U.S. and China.

The company is pre-revenue, generating no product sales; its economics depend on future commercialization of pipeline candidates or partnership/out-licensing transactions. It has raised approximately $131 million in cumulative venture funding, led most recently by a $25 million Series B extension from Triwise Capital with Proxima Ventures, LLS TAP, and Wuxi Biologics. Customers in the commercial sense do not yet exist; revenue-relevant counterparties today are clinical trial sites and patients, with future end-customers expected to be oncologists, specialty pharmacies, and ultimately payers covering oncology and immunology indications.

Immune-Onc Therapeutics firmographics

Firmographics
Name
Immune-Onc Therapeutics
Legal name
Immune-Onc Therapeutics, Inc.
Website
https://immune-onc.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class antibody therapeutics that target myeloid cell inhibitory receptors (the LILRB family) to treat blood cancers, solid tumors, and autoimmune diseases.
Ownership category
akta.pro rank

Immune-Onc Therapeutics industry classification

Industry
Product category
Cancer Immunotherapy / Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Myeloid checkpoint inhibitors
  • Cancer immunotherapy antibodies
  • Biopharmaceutical drug development
  • Oncology therapeutics pipeline
  • LILRB-targeted therapies

Where Immune-Onc Therapeutics is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Immune-Onc Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical/Biologic Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company. Revenue expected from commercialization of novel myeloid checkpoint inhibitor therapies upon regulatory approval. Pipeline includes IO-108 (Phase 1b/2 solid tumors), IO-202 (Phase 1b blood cancers), IO-106 (preclinical), IO-312 (preclinical).

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Immune-Onc Therapeutics product offering

Product offering

Core offering

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of first-in-class therapeutic monoclonal antibodies that target the LILRB family of myeloid cell inhibitory receptors to treat cancer. Its lead clinical-stage candidates are IO-108 (anti-LILRB2 for solid tumors including hepatocellular carcinoma) and IO-202 (anti-LILRB4 for AML, CMML and solid tumors), supplemented by preclinical candidates IO-106 (anti-LAIR1) and IO-312 (LILRB4 x CD3 bispecific).

Product overview

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of novel myeloid checkpoint inhibitors targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB). The pipeline includes IO-108 (anti-LILRB2 for solid tumors), IO-202 (anti-LILRB4 for AML/CMML), IO-106 (anti-LAIR1 for solid tumors), and IO-312 (bispecific anti-LILRB4/CD3 for hematologic malignancies). The company focuses on antibodies that modulate or deplete specific subsets of myeloid cells involved in cancer pathogenesis.

Differentiator

Problem solved

Functional benefit

Products and services

  • IO-108 IO-108 is a fully human IgG4 monoclonal antibody with high affinity and specificity towards LILRB2 (ILT4). It blocks interaction with multiple ligands (HLA-G, ANGPTLs, SEMA4A, CD1d) involved in cancer-associated immune suppression, functioning as a myeloid checkpoint inhibitor to promote innate and adaptive anti-cancer immunity. It is currently in Phase 1b/2 clinical development for solid tumors including hepatocellular carcinoma.
  • IO-202 IO-202 is a first-in-class humanized IgG1 antagonist antibody that binds LILRB4 (ILT3) with high affinity and depletes LILRB4-positive cells via antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). It converts 'don't kill me' to 'kill me' signals by activating T cell killing, and inhibits infiltration of blood cancer cells. It is in Phase 1b development for acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors.
  • IO-106 IO-106 is a first-in-class antagonist monoclonal antibody targeting LAIR1 (Leukocyte-Associated Immunoglobulin-Like Receptor 1). It reverses collagen-mediated immune suppression on T cells and myeloid cells in the solid tumor microenvironment, with broad potential in collagen-rich solid tumors.
  • IO-312 IO-312 is a first-in-class LILRB4-directed bispecific monoclonal antibody with high affinity binding to LILRB4 and low affinity binding to CD3. The differential affinity design maximizes anti-tumor effect while minimizing cytokine release-related toxicities. It has cross-reactivity to non-human primate LILRB4 and CD3 to enable preclinical toxicology assessment, with potential application in AML and other hematologic malignancies.

Quantifiable outcome

  • IO-202 in CMML: 50% CR rate, 66.7% ORR in 18 evaluable patients vs. 7-17% CR rate for existing therapies
  • +4 more outcomes

Companies that use Immune-Onc Therapeutics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Immune-Onc Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Immune-Onc Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered major, core and minor.

  • RochemajorStrategic or Co-development Partner · 20 February 2024Clinical trial collaboration for IO-108 in global Phase 1b/2 study. Roche sponsors and conducts the trial evaluating IO-108 with atezolizumab and bevacizumab for first-line hepatocellular carcinoma treatment as part of Roche's Morpheus-Liver program. Roche provides clinical supply and manages study operations.
  • Regeneron PharmaceuticalsmajorStrategic or Co-development Partner · 17 October 2022Clinical supply agreement for IO-108 in combination with Regeneron's anti-PD-1 therapy Libtayo (cemiplimab). Regeneron provides cemiplimab for ongoing clinical development program; Immune-Onc retains global rights to IO-108.
  • BeiGenemajorStrategic or Co-development Partner · 10 October 2022Clinical trial collaboration and supply agreement to evaluate IO-108 and IO-202 in combination with BeiGene's anti-PD-1 antibody tislelizumab in China. Immune-Onc sponsors and funds clinical trials; BeiGene provides tislelizumab.
  • University of Texas Southwestern Medical CentercoreStrategic or Co-development PartnerStrategic research collaboration with academic institution; scientific founder Dr. Chengcheng (Alec) Zhang is faculty member. Pioneering research on LILRB family published in Nature.
  • Albert Einstein College of MedicineminorStrategic or Co-development PartnerStrategic research collaboration for myeloid checkpoint target research and validation.
  • Memorial Sloan Kettering Cancer CenterminorStrategic or Co-development PartnerStrategic research collaboration for oncology research programs.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Immune-Onc Therapeutics competitors and assessment

Company assessment

Direct peers

  • Pionyr Immunotherapeutics: Pionyr is a clinical-stage biotech developing antibody therapeutics that target myeloid cell receptors in the tumor microenvironment (TREM2, TREM1). It competes with Immune-Onc on the same thesis of depleting or reprogramming suppressive myeloid cells to enable anti-tumor immunity.
  • Compugen: Compugen uses computational biology to identify novel immune checkpoints, including myeloid targets such as PVRIG and TIGIT-axis pathways. Both companies pursue novel checkpoint biology discovered through proprietary target-identification platforms and translate them into antibody therapeutics.
  • Trillium Therapeutics (Pfizer): Trillium developed SIRPα/CD47 myeloid checkpoint inhibitors for hematologic malignancies before being acquired by Pfizer. It is the most advanced direct precedent for a small-cap biotech successfully translating myeloid checkpoint biology into pivotal-stage assets, directly comparable to Immune-Onc's LILRB strategy.
  • Surface Oncology: Surface Oncology developed immuno-oncology antibodies targeting myeloid and stromal cells in the tumor microenvironment, including ILT-related programs. Its pipeline and scientific rationale closely overlap with Immune-Onc's LILRB-directed approach.
  • Innate Pharma: Innate Pharma develops antibody-based immunotherapies targeting myeloid and NK cell pathways for cancer. Its focus on innate immune modulation (e.g., NKG2A) places it in direct strategic overlap with Immune-Onc's myeloid checkpoint thesis.
  • Arcus Biosciences: Arcus is a clinical-stage immuno-oncology company with programs targeting adenosine (CD73/A2AR) and other myeloid-suppressive pathways. It competes for the same combination-therapy slot in tumors like HCC where Immune-Onc's IO-108 is being evaluated alongside checkpoint inhibitors.

Regional players

  • Nkarta: Nkarta is a clinical-stage cell therapy company developing allogeneic NK cell therapies for hematologic malignancies including AML. While the modality (cell therapy vs. antibody) and target cell type differ, it overlaps with Immune-Onc in clinical indication (AML/CMML) and in the strategy of redirecting innate immunity against blood cancers.

Emerging players

  • Mereo BioPharma: Mereo is a clinical-stage biopharma developing therapies for rare hematologic conditions and cancers, including AML. It overlaps with Immune-Onc on indication strategy in myeloid blood cancers and on the orphan-drug, accelerated-approval playbook.
  • Werewolf Therapeutics: Werewolf is developing tumor-microenvironment-activated immunotherapies (PREDATOR platform) that deliver immune agonists selectively into the tumor. It is comparable as another small-cap IO biotech targeting the same tumor-microenvironment biology that Immune-Onc addresses via myeloid checkpoints.
  • Bolt Biotherapeutics: Bolt develops immune-stimulating antibody-drug conjugates (ISACs) designed to activate myeloid cells in the tumor microenvironment. While the modality differs from naked mAbs, both companies target the same biological insight: engaging myeloid cells to convert cold tumors to hot.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks3 records

Key highlights14 records

Customer concentration

Immune-Onc Therapeutics social profiles

Digital presence

Immune-Onc Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Immune-Onc Therapeutics leadership team

Management profile

Number of profiles

Profiles16 records

Immune-Onc Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Immune-Onc Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immune-Onc Therapeutics

What does Immune-Onc Therapeutics do?

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of first-in-class therapeutic monoclonal antibodies that target the LILRB family of myeloid cell inhibitory receptors to treat cancer. Its lead clinical-stage candidates are IO-108 (anti-LILRB2 for solid tumors including hepatocellular carcinoma) and IO-202 (anti-LILRB4 for AML, CMML and solid tumors), supplemented by preclinical candidates IO-106 (anti-LAIR1) and IO-312 (LILRB4 x CD3 bispecific).

Is Immune-Onc Therapeutics a public or private company?

Immune-Onc Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Immune-Onc Therapeutics founded?

Immune-Onc Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Immune-Onc Therapeutics based?

Immune-Onc Therapeutics is headquartered in Palo Alto, United States, in the North America region.

How does Immune-Onc Therapeutics make money?

One revenue line is on record: pharmaceutical/Biologic Development and Commercialization.

Who are Immune-Onc Therapeutics's main competitors?

Direct peers on record are Pionyr Immunotherapeutics, Compugen, Trillium Therapeutics (Pfizer), Surface Oncology, Innate Pharma and Arcus Biosciences. Nkarta is listed as a regional player. Emerging players are Mereo BioPharma, Werewolf Therapeutics and Bolt Biotherapeutics.

Does Immune-Onc Therapeutics have an API?

No public API is recorded for Immune-Onc Therapeutics.

What industry is Immune-Onc Therapeutics in?

Immune-Onc Therapeutics's product category is Cancer Immunotherapy / Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals